2006
Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma
Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG. Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma. Journal Of Immunotherapy 2006, 29: 95-101. PMID: 16365605, DOI: 10.1097/01.cji.0000195295.74104.ad.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCancer VaccinesDose-Response Relationship, DrugFemaleGp100 Melanoma AntigenHumansInterleukin-2Leukocytes, MononuclearMaleMelanomaMembrane GlycoproteinsMiddle AgedNeoplasm Recurrence, LocalPeptide FragmentsPeptidesSkin NeoplasmsConceptsLow-dose IL-2G209-2MG209-2M peptideHigh-dose IL-2Phase 2 studyAdvanced melanomaInterleukin-2T cellsHigh-dose interleukin-2Low-dose interleukin-2Melanoma tumor-infiltrating lymphocytesGrade 4 toxicityMelanoma peptide vaccineSubcutaneous IL-2Grade 2 toxicityGrade 3 toxicityTumor-infiltrating lymphocytesEnzyme-linked immunospotHuman leukocyte antigenDifferent toxicity profilesM peptideSignificant biologic effectsTetramer analysisToxic deathsMost patients
2001
Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial
Bear H, Roberts J, Cornell D, Tombes M, Kyle B. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial. Cancer Immunology, Immunotherapy 2001, 50: 269-274. PMID: 11499810, PMCID: PMC11036846, DOI: 10.1007/s002620100199.Peer-Reviewed Original ResearchConceptsIL-2 infusionAdoptive immunotherapyClinical trialsInterleukin-2Low-dose interleukin-2Tumor-sensitized T cellsPhase I clinical trialLymph node cellsPilot clinical trialLymph node lymphocytesTarget cell numberCell numberNode lymphocytesNode cellsTumor regressionT cellsT lymphocytesUnexpected toxicitiesMurine modelAdditional trialsInfusionPhase ITrialsTechnical modificationsPatient cells
1994
Increased Systemic, but Not Regional, Neopterin Production Following Intraperitoneral Administration of Interleukin-2 and Lack of Effect of Pterins upon the Lymphokine-Activated Killer Cell Phenomenon
Roberts J, Bigelow J, Moore A, Belinson J, Stewart J, Hacker M. Increased Systemic, but Not Regional, Neopterin Production Following Intraperitoneral Administration of Interleukin-2 and Lack of Effect of Pterins upon the Lymphokine-Activated Killer Cell Phenomenon. Journal Of Immunotherapy 1994, 15: 53-58. PMID: 8110731, DOI: 10.1097/00002371-199401000-00007.Peer-Reviewed Original ResearchConceptsLymphokine-activated killer cellsNeopterin productionInterleukin-2Killer cellsIntraperitoneal interleukin-2Killer cell phenomenonUrinary neopterin excretionRoute of administrationActivated T cellsPresence of neopterinNumber of cytokinesLack of effectN-acetyl serotoninIncreased SystemicNeopterin excretionOvarian carcinomaT cellsImmune responseClinical administrationNeopterinCytotoxic effectsAdministrationSynthesis inhibitorCell phenomenonCells